Study summary
Sparsentan also lowered proteinuria in genetic forms of FSGS
What was tested
A post hoc analysis of DUPLEX in people with FSGS caused by podocyte gene variants, COL4A3-5 variants or high-risk APOL1 genotypes.
What they found
- Sparsentan gave substantial, sustained proteinuria reductions in genetic FSGS, which usually resists immunosuppression.
- Fewer reached the composite kidney endpoint than with irbesartan.
What it means
Suggests a role for sparsentan where immune drugs do not help.
Last reviewed 2026-11-16 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.